Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas B Muchmore

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Journal of Diabetes Science and Technology|January 3, 2018
Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?Douglas B Muchmore
Journal of Diabetes Science and Technology|March 7, 2017
The Need for Faster InsulinDouglas B Muchmore
Journal of Diabetes Science and Technology|August 28, 2012
Ultrafast-acting insulins: state of the artLutz Heinemann, Douglas B Muchmore
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 6, 2011
Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusionDaniel E Vaughn, Douglas B Muchmore
Diabetes, Obesity & Metabolism|October 10, 2006
Inhaled insulin delivery--where are we now?Douglas B Muchmore, Jeffrey R Gates
Journal of Diabetes Science and Technology|March 24, 2010
Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulationsDouglas B Muchmore, Daniel E Vaughn
Journal of Diabetes Science and Technology|August 28, 2012
Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidaseDouglas B Muchmore, Daniel E Vaughn
Diabetes Care|January 29, 2011
Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Diabetes Technology & Therapeutics|July 10, 2007
The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic dataDouglas B Muchmore, Bernard Silverman, Amparo De La Peña, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2018
Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy SubjectsSanna Rosengren, Jennifer Souratha, Dave Conway, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Journal of Diabetes Science and Technology|January 3, 2018
Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?Douglas B Muchmore
Journal of Diabetes Science and Technology|March 7, 2017
The Need for Faster InsulinDouglas B Muchmore
Journal of Diabetes Science and Technology|August 28, 2012
Ultrafast-acting insulins: state of the artLutz Heinemann, Douglas B Muchmore
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 6, 2011
Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusionDaniel E Vaughn, Douglas B Muchmore
Diabetes, Obesity & Metabolism|October 10, 2006
Inhaled insulin delivery--where are we now?Douglas B Muchmore, Jeffrey R Gates
Journal of Diabetes Science and Technology|March 24, 2010
Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulationsDouglas B Muchmore, Daniel E Vaughn
Journal of Diabetes Science and Technology|August 28, 2012
Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidaseDouglas B Muchmore, Daniel E Vaughn
Diabetes Care|January 29, 2011
Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Diabetes Technology & Therapeutics|July 10, 2007
The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic dataDouglas B Muchmore, Bernard Silverman, Amparo De La Peña, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2018
Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy SubjectsSanna Rosengren, Jennifer Souratha, Dave Conway, et al.
Pageof 4